Quick summary
Kisspeptin-10 is the shortest bioactive kisspeptin fragment and the master upstream regulator of GnRH controlling the reproductive hormone cascade. Clinical studies show it acutely increases LH and testosterone in men and is being investigated for fertility diagnostics.
Overview
Kisspeptin-10 is the shortest bioactive fragment of kisspeptin, a neuropeptide that plays a central role in the initiation of puberty and regulation of the reproductive axis. It is the master upstream regulator of gonadotropin-releasing hormone (GnRH), making it a key switch in the hormonal cascade that controls testosterone, estrogen, LH, and FSH production. It is being studied as a diagnostic tool and therapeutic for reproductive disorders.
Mechanism of action
Kisspeptin-10 binds to the KISS1R (GPR54) receptor on GnRH neurons in the hypothalamus, triggering the release of GnRH. This initiates the hypothalamic-pituitary-gonadal (HPG) axis cascade: GnRH stimulates LH and FSH release from the pituitary, which in turn stimulates testosterone/estrogen production in the gonads. Kisspeptin acts as the 'master switch' of this entire system — without kisspeptin signaling, puberty does not occur.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| hormonal optimization / LH stimulation | subcutaneous | 100–500 mcg | 1-2x daily | Limited community dosing data. Clinical studies use IV bolus or continuous infusion. Subcutaneous is common in biohacking contexts. Short cycles only. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Clinical studies demonstrate that kisspeptin-10 administration acutely increases LH and testosterone levels in men. Dhillo et al. (2005, JCEM) showed that IV kisspeptin-10 potently stimulated gonadotropin release in healthy men. Studies in women show stimulation of LH pulses. Being investigated as a diagnostic test for pubertal disorders and as a fertility treatment. Imperial College London leads clinical research. Safety data from clinical trials is favorable — well-tolerated with predictable hormonal responses.[1][2][3]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Kisspeptin-10 for synergistic effects.
Legal status
Not FDA-approved. In clinical investigation at multiple academic centers. Available as a research peptide. Not scheduled.
Sourcing & access
Research compound
Kisspeptin-10 is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Kisspeptin-10 is a 10-amino acid neuropeptide and the shortest bioactive fragment of kisspeptin. It is the master switch of the hypothalamic-pituitary-gonadal axis, triggering GnRH release which controls testosterone, estrogen, LH, and FSH production.
Kisspeptin-10 binds to KISS1R (GPR54) receptors on GnRH neurons in the hypothalamus, triggering GnRH release. This initiates the HPG axis cascade: GnRH stimulates LH and FSH from the pituitary, which stimulates testosterone or estrogen production in the gonads.
Clinical trial safety data from academic centers led by Imperial College London is favorable, with kisspeptin-10 well tolerated and producing predictable hormonal responses. Reported side effects include injection site discomfort, hot flashes, abdominal discomfort, and headache. No serious adverse events have been documented, though long-term human exposure data remains limited.
Yes. Clinical studies by Dhillo et al. showed that IV kisspeptin-10 potently stimulated gonadotropin release and acutely increased LH and testosterone levels in healthy men. Imperial College London leads ongoing clinical research.